Genetic Testing for Successive Cancer Treatment

被引:11
作者
Singh, Desh Nidhi [1 ]
Daripelli, Sushma [2 ,3 ,4 ]
Bushara, Mohamed Osman Elamin [5 ]
Polevoy, Georgiy Georgievich [6 ]
Prasanna, Muthu [7 ]
机构
[1] Rama Med Coll Hosp & Res Ctr, Microbiol, Kanpur, India
[2] Govt Med Coll GMC Jangaon, Anat, Jangaon, India
[3] Gandhi Med Coll, Anat, Hyderabad, India
[4] All India Inst Med Sci, Anat, Bibinagar, India
[5] Umm Al Qura Univ, Hlth Promot & Hlth Educ, Mecca, Saudi Arabia
[6] Moscow Polytech Univ, Dept Phys Educ, Moscow, Russia
[7] Surya Grp Educ Inst, Surya Sch Pharm, Pharmaceut Including Pharmaceut Biotechnol, Villupuram, India
关键词
cancer genetics; oncology; clinical cancer genetics; study of inherited cancer syndromes; cancer genetic testing; BREAST-CANCER; RET PROTOONCOGENE; DECISION-MAKING; OVARIAN-CANCER; RISK; DISEASE; BRCA1; MUTATION; SUSCEPTIBILITY; ATTITUDES;
D O I
10.7759/cureus.49889
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer genetic testing is a revolutionary medical approach that involves the assessment of genetic markers in asymptomatic individuals to predict their future susceptibility to cancer. This paradigm shift in early detection and intervention has the potential to profoundly alter our strategies for cancer prevention and treatment. One pivotal area where genetic testing can have a significant impact is among families with a hereditary predisposition to cancer. Recent research has seen a surge in the exploration of how individuals perceive their cancer risk within the realm of cancer genetics. This proactive approach to genetic testing allows healthcare professionals to identify family members who may carry the same cancer-related genetic mutations, empowering them to make informed decisions regarding their healthcare and cancer risk management. Genetic testing for cancer-related disorders has significantly improved in accuracy and affordability, potentially revolutionizing monitoring and treatment methods. The expanding knowledge of genetic mutations associated with cancer susceptibility has driven significant progress in cancer therapy. Identifying numerous major cancer susceptibility genes has propelled predictive genetic testing, providing individuals with valuable insights into their genetic predisposition to cancer. While perceived risk plays a vital role in genetic counseling, it is equally essential to offer comprehensive information about the advantages and potential risks associated with genetic testing. Ensuring that individuals have a clear understanding of the benefits and potential drawbacks of genetic testing is imperative for making informed healthcare decisions. In our comprehensive review, researchers explored several critical aspects of genetic testing in the context of cancer, including awareness and knowledge, the communication of cancer genetic risk, genetic testing for inherited cancer syndromes, and the challenges and limitations linked to genetic testing. Through this examination, we aim to illuminate the transformative potential of genetic testing in cancer prevention and treatment.
引用
收藏
页数:12
相关论文
共 50 条
[1]   What hinders minority ethnic access to cancer genetics services and what may help? [J].
Allford, Anna ;
Qureshi, Nadeem ;
Barwell, Julian ;
Lewis, Celine ;
Kai, Joe .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2014, 22 (07) :866-874
[2]   Prioritizing targets for precision cancer medicine [J].
Andre, F. ;
Mardis, E. ;
Salm, M. ;
Soria, J. -C. ;
Siu, L. L. ;
Swanton, C. .
ANNALS OF ONCOLOGY, 2014, 25 (12) :2295-2303
[3]   A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing - Commentary [J].
Botkin, JR ;
Croyle, RT ;
Smith, KR ;
Baty, BJ ;
Lerman, C ;
Goldgar, DE ;
Ward, JM ;
Flick, BJ ;
Nash, JE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (13) :872-882
[4]   American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility [J].
Bruinooge, SS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2397-2406
[5]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].
Burke, W ;
Daly, M ;
Garber, J ;
Botkin, J ;
Kahn, MJE ;
Lynch, P ;
McTierman, A ;
Offit, K ;
Perlman, J ;
Petersen, G ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003
[6]   The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22 [J].
Camaschella, C ;
Roetto, A ;
Cali, A ;
De Gobbi, M ;
Garozzo, G ;
Carella, M ;
Majorano, N ;
Totaro, A ;
Gasparini, P .
NATURE GENETICS, 2000, 25 (01) :14-15
[7]  
Codori AM, 1999, CANCER EPIDEM BIOMAR, V8, P345
[8]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[9]   Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility:: Findings from p53 and BRCA1 testing programs [J].
Dorval, M ;
Patenaude, AF ;
Schneider, KA ;
Kieffer, SA ;
DiGianni, L ;
Kalkbrenner, KJ ;
Bromberg, JI ;
Basili, LA ;
Calzone, K ;
Stopfer, J ;
Weber, BL ;
Garber, JE .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2135-2142
[10]   Optimising clinical practice in cancer genetics with cultural competence: lessons to be learned from ethnographic research with Chinese-Australians [J].
Eisenbruch, M ;
Yeo, SS ;
Meiser, B ;
Goldstein, D ;
Tucker, K ;
Barlow-Stewart, K .
SOCIAL SCIENCE & MEDICINE, 2004, 59 (02) :235-248